The Staphylococcus aureus bacteraemia Network Adaptive Platform Trial is an innovative trial to evaluate a range of interventions with the aim of improving outcomes for patients with Staphylococcus aureus bacteraemia (AKA bloodstream infections).
This trial will include both adults and children.
The study includes sites from throughout Australia, New Zealand, Singapore, Canada, Israel and the UK and has the potential to include sites elsewhere in the world.
Professor Joshua S Davis PhD, FRACP, MBBS (Hons), DTM&H, Grad Cert Pop Health. Infectious Diseases Physician and NHMRC Career Development Fellow at the University of Newcastle and the Menzies School of Health Research.
Professor Steven YC Tong PhD, FRACP, MBBS (Hons), Grad Dip Epidemiol Biostats, Infectious Diseases Physician with the Victorian Infectious Diseases Service.
Presentation by Dr Brad Spellberg, Chief Medical Officer at the Los Angeles County-University of Southern California (LAC+USC) Medical Center.
On this day last year, the SNAP trial started recruitment. 12 months on, more than 450 participants have joined the study, already making it the second largest clinical trial for Staphylococcus aureus bloodstream infections in the world.
Staphylococcus aureus can cause sepsis, among other infections, and sends more than 450 Australian babies, children and teenagers to hospital annually, according to Telethon Kids Institute.
